Oyster Point Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for OYSTER POINT PHARMA, and when can generic versions of OYSTER POINT PHARMA drugs launch?
OYSTER POINT PHARMA has one approved drug.
There are ten US patents protecting OYSTER POINT PHARMA drugs.
There are thirty-five patent family members on OYSTER POINT PHARMA drugs in twenty countries and two supplementary protection certificates in two countries.
Summary for Oyster Point Pharma
| International Patents: | 35 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Oyster Point Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oyster Point Pharma | TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978-001 | Oct 15, 2021 | RX | Yes | Yes | 9,504,645 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Oyster Point Pharma | TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978-001 | Oct 15, 2021 | RX | Yes | Yes | 11,224,598 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Oyster Point Pharma | TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978-001 | Oct 15, 2021 | RX | Yes | Yes | 11,903,943 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Oyster Point Pharma | TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978-001 | Oct 15, 2021 | RX | Yes | Yes | 9,532,944 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Oyster Point Pharma | TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978-001 | Oct 15, 2021 | RX | Yes | Yes | 11,903,942 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Oyster Point Pharma | TYRVAYA | varenicline tartrate | SPRAY;NASAL | 213978-001 | Oct 15, 2021 | RX | Yes | Yes | 10,456,396 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Oyster Point Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 201790893 | ⤷ Subscribe |
| China | 111956650 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2016064759 | ⤷ Subscribe |
| Spain | 2848977 | ⤷ Subscribe |
| Australia | 2015336216 | ⤷ Subscribe |
| Denmark | 3848028 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Oyster Point Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1044189 | 08C0039 | France | ⤷ Subscribe | PRODUCT NAME: VARENICLINE OU L?UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, NOTAMMENT LE TARTRATE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/360/001 DU 20060926; REGISTRATION NO/DATE AT EEC: EU/1/06/360/001 DU 20060926 |
| 1044189 | SPC/GB08/034 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: VARENICLINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE TARTRATE SALT; REGISTRATION NO/DATE: EU/1/06/360/001 - 010 20060928 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
